

VH
VL
CH1
CL
VH
CH1
VL
CL
Anti-TA
Anti-CD3

FIG. 1B



Protease
CLV
CH2
CH3
CH2
CH3
VH
CH1
VH
CH1
VL
CL
VL
CL
CLV
Anti-TA
Anti-CD3

FIG. 1A




FIG. 1E

FIG. 1D

FIG. 1C



CLV
CLV
CLV
MASK
CLV
V_H
C_{H1}
V_L
C_L
C_{H2}
C_{H3}

FIG. 1G



MASK
CLV
CLV
CLV
CLV
V_H
C_{H1}
V_L
C_L
C_{H2}
C_{H3}
Anti-CD3
Anti-TA

FIG. 1F



VH
CH1
VL
CL
L
Anti-TA
Anti-CD3

FIG. 2B



Protease
CLV
VH
CH1
VL
CL
CH2
CH3
Anti-TA
Anti-CD3

FIG. 2A



VH
VL
CH1
CL
VH
CH1
VL
CL
Anti-CD3
Anti-TA

FIG. 3B



MASK
Protease
CLV
CLV
CLV
VH
CH1
VL
CL
VH
CH1
VL
CL
CH2
CH3
CH2
CH3
Anti-CD3
Anti-TA

FIG. 3A



CH2
CH3
CH2
CH3
CLV
VH
CH1
CLV
VH
CH1
VL
CL
VL
CL

FIG. 4B



CH2
CH3
CH2
CH3
CLV
VH
CH1
VH
CH1
VL
CL
VL
CL
CLV
Anti-TA or CD3
Anti-CD3 or TA

FIG. 4A




FIG. 4C



CLV
CLV
CLV
CLV
CH2
CH3
CH2
CH3
VH
VL
CH1
CL
VH
VL
CH1
CL

FIG. 4E



CLV
CLV
CLV
CH2
CH3
CH2
CH3
VH
VL
CH1
CL
VH
VL
CH1
CL
Anti-TA or CD3
Anti-CD3 or TA

FIG. 4D



TA*Ab
VL
VH
CL
CH1
CH2
CH3
CLV
Anti-TA or CD3
Anti-CD3 or TA

FIG. 4F



TA*Ab
VL
VH
CL
CH1
CH2
CH3
CLV
Anti-TA or CD3
Anti-CD3 or TA

FIG. 4G





FIG. 4I






FIG. 4H




FIG. 5A

FIG. 5B

FIG. 5C

FIG. 5D



VH
VL
CH1
CL
t1/2

FIG. 6B



Protease
CLV
CH2
CH3
VH
CH1
VL
CL
Anti-TA
Anti-CD3

FIG. 6A



VH
CH1
VL
CL
t1/2

FIG. 7B



Protease
CLV
CLV
VH
CH1
VL
CL
CH2
CH3
Anti-TA
Anti-CD3

FIG. 7A




FIG. 8C

FIG. 8B

FIG. 8A




FIG. 8F

FIG. 8E

FIG. 8D




FIG. 8I

FIG. 8H

FIG. 8G




FIG. 8L

FIG. 8K

FIG. 8J




FIG. 9A

FIG. 9B

FIG. 9C




FIG. 10A

FIG. 10B




FIG. 10C

FIG. 10D



Cleavable Linker
Anti-CD3 Mask
Anti-TA Mask
TA*Ab
CD3 Fab
TA Fab

FIG. 11A




FIG. 11B



Cleavable Linker
Anti-CD3 Mask
Anti-TA Mask
TA*Ab
VH
VL
CH1
CL
CH2
CH3
TA Fab
CD3 Fab

FIG. 11C




FIG. 11D



Jurkat Binding
15000
10000
5000
0
MFI_APC
TAAxCD3 not treated
TAAxCD3 protease treated
Isotype control
-13
-12
-11
-10
-9
-8
-7
Molecule Concentration Log10 (M)

FIG. 12A




FIG. 12A
CONTINUED




FIG. 12C




FIG. 12B




FIG. 12E




FIG. 12D




FIG. 13B




FIG. 13A




FIG. 14B




FIG. 14A




FIG. 15A

FIG. 15B







FIG. 15D






FIG. 15C



Varying Linker Lengths: Fc-CD3-TA
RLU
2500000
2000000
1500000
1000000
500000
0
10-14
10-13
10-12
10-11
10-10
10-9
10-8
10-7
Ab Concentration (M)
Figure 4E Structure with (G4S)1
Figure 4I Structure with (G4S)1
Figure 4E Structure with (G4S)2
Figure 4I Structure with (G4S)2
Figure 4E Structure with (G4S)3
Figure 4I Structure with (G4S)3
(G4S)X refers to the linker length of the non-cleavable linker connecting the Fabs

FIG. 16




FIG. 17